secwatch.observer — SEC 8-K summary
======================================

Issuer:     INOVIO PHARMACEUTICALS, INC. (INO)
CIK:        0001055726
Form:       8-K
Filed at:   2023-05-18T23:59:59+00:00
Accession:  0001193125-23-148122
Event type: other_material
Sentiment:  neutral
Materiality: 0.55
Item codes: 5.02, 5.07, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Inovio shareholders approve 2023 Omnibus Incentive Plan; elect directors with notable withhold for Zoth
--------------------------------------------------------------------------------

- Stockholders approved the 2023 Omnibus Incentive Plan (14M new shares plus prior plan returning shares).
- All eight director nominees elected; Lota Zoth received 36.4M withheld vs 57.4M votes for.
- Ratification of Ernst & Young as independent auditor for FY2023: 155.6M for, 4.0M against.
- Non-binding say-on-pay passed (60.4M for, 32.2M against); annual frequency selected for future votes.
- Board determined to hold advisory votes on executive compensation every year going forward.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1055726/000119312523148122/0001193125-23-148122-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1055726/000119312523148122/d458280d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-148122

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer